Description: BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Home Page: www.biomarin.com
770 Lindaro Street
San Rafael,
CA
94901
United States
Phone:
415 506 6700
Officers
Name | Title |
---|---|
Mr. Alexander Hardy | President, CEO & Director |
Mr. Brian R. Mueller CPA | CFO & Executive VP |
Dr. C. Greg Guyer Ph.D. | Executive VP & CTO |
Dr. Henry J. Fuchs M.D., Ph.D. | Advisor |
Ms. Erin Burkhart | Group VP & Chief Accounting Officer |
Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development |
Ms. Traci McCarty | Group Vice President of Investor Relations |
Mr. George Eric Davis J.D. | Executive VP, Chief Legal Officer, General Counsel & Secretary |
Ms. Humaira Serajuddin | Senior VP & Chief Marketing Officer |
Ms. Amy Wireman | Executive VP & Chief People Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 17.094 |
---|---|
Trailing PE: | 39.7197 |
Price-to-Book MRQ: | 2.3239 |
Price-to-Sales TTM: | 4.3573 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 3401 |